Mizuho raises Molina Healthcare stock price target on solid quarter By Investing.com

Mizuho raised Molina Healthcare’s price target to $195 from $170 while keeping an Outperform rating, citing a solid quarter and easing concern about Medicaid disenrollment risk. Molina reported Q1 2026 adjusted EPS of $2.35 versus $2.17 expected, an 8.29% beat, though revenue of $10.8 billion slightly missed the $10.87 billion consensus. Management said first-quarter 2026 cost trends were annualizing below the 5% embedded in guidance, supporting better earnings visibility.

Analysis

The market is repricing MOH as a cleaner earnings compounder, but the real signal is that the downside from membership churn is proving less toxic than feared. If the disenrollment mix is broadly average, then the bear case loses its main lever: a hidden acuity spike that would have forced higher utilization and margin compression for multiple quarters. That shifts MOH from a “prove it every quarter” story to one where rate adequacy and utilization management can compound into visible EPS revisions.

The second-order winner is not just MOH, but managed-care peers exposed to Medicaid renewal noise if states are allowing tighter utilization control and rate increases are catching up. Conversely, the losers are providers and downstream service vendors most leveraged to Medicaid volume, because a more disciplined payer posture can suppress utilization without necessarily impairing headline enrollment as much as feared. The key nuance is timing: the earnings power inflection is likely a months-long rerating process, while any one-quarter enrollment disappointment should now be treated more as noise than thesis breakage.

The contrarian read is that the stock may not be “cheap” because it is misunderstood, but because investors are still anchoring to a past regime where Medicaid mix shocks were the dominant risk. If cost trends are peaking, consensus may be underestimating how quickly MOH’s multiple can expand once investors model a flatter medical cost curve plus less downside from redeterminations. The risk is that the apparent stabilization is temporary and states re-tighten rates or utilization rules, which would matter more over 2-3 quarters than in the next few days.

Key Decisions for Investors

• Go long MOH on pullbacks over the next 1-2 weeks; target a 3-6 month hold where rerating can come from estimate revisions rather than multiple expansion alone. Risk/reward looks attractive if downside is capped by the market’s reduced fear of adverse Medicaid mix, but trim if the stock reclaims recent highs without follow-through in estimate revisions.
• Buy MOH call spreads expiring in 3-6 months to express upside with defined risk; structure for a move toward the next analyst target band rather than chasing spot. Best if implied vol remains elevated from the post-earnings rerate.
• Pair trade: long MOH / short a Medicaid-exposed provider or managed-care name with less rate protection over the next 1-2 quarters. The edge is that MOH appears to have better control over utilization and better earnings visibility, while the short should lag if renewal noise turns out to be less damaging than consensus expects.
• Use a tactical stop-loss on any MOH long if the next update shows cost trends re-accelerating above guidance assumptions; that would invalidate the current ‘peaking’ narrative. In that case, expect the market to compress the multiple quickly because the bull thesis is built on stability, not growth.